The company’s site says it is approaching chronic inflammatory diseases like asthma and chronic obstructive pulmonary disease by modifying them rather than suppressing systems.
The new website encourages patient interaction and education about COPD.
The FDA has approved Striverdi Respimat (olodaterol) inhalation spray to treat patients with COPD, including chronic bronchitis and/or emphysema that are experiencing airflow obstruction.
An exercise program that increases COPD patients’ ability to perform physical activity with a lessened sensation of dyspnea is a primary goal of rehabilitation.
Obesity, especially excessive belly fat, is a risk factor for COPD, according to an article in the Canadian Medical Association Journal.
Patients with COPD may need more education and better dialogue with their physicians to effectively manage the disease and potentially life-threatening exacerbations, according to the national COPE (Chronic Obstructive Pulmonary Experience) Survey released by the COPD Foundation.
As healthcare costs and hospital readmissions continue to rise, the field of respiratory care has begun to embrace the advantages of home care solutions for chronic lung patients.
As the number of chronic lung patients continues to grow, today’s aerosol therapy products are providing high-quality, cost-efficient medication delivery.
The COPD Foundation has launched the inaugural issue of its new open access, peer-reviewed journal: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation.
The prevalence of heart failure is significantly higher in patients with COPD, and the risk is especially high among African-American patients with COPD, according to a new study from the Morehouse School of Medicine in Atlanta.